Ethical Considerations in IgA Nephropathy Management
The most critical ethical considerations in IgA nephropathy center on informed consent for immunosuppression, equitable access to clinical trials, and balancing treatment benefits against serious adverse effects, particularly when considering corticosteroids in patients with eGFR <50 ml/min/1.73 m².
Informed Consent and Shared Decision-Making
Risk-Benefit Discussions for Immunosuppression
All patients being considered for immunosuppression must receive a detailed discussion of risks and benefits, with explicit recognition that adverse treatment effects are more likely in patients with eGFR <50 ml/min/1.73 m² 1.
The uncertainty surrounding safety and efficacy of existing immunosuppressive treatments creates an ethical obligation to present this equipoise honestly to patients 1.
Corticosteroid therapy carries important treatment-emergent toxicity risks that must be thoroughly discussed, particularly in vulnerable populations with reduced kidney function 1.
Use of Prognostic Tools in Patient Counseling
The International IgAN Prediction Tool should be used as a resource to quantify progression risk and inform shared decision-making, though it cannot predict treatment response 1.
Risk stratification using clinical and histologic data enables transparent conversations about disease trajectory and treatment urgency 1.
Patients with lower risk disease can be counseled on gradual progression over years to decades, while higher-risk patients need preparation for potential kidney replacement therapy 1.
Clinical Trial Access and Equity
Ethical Imperative for Trial Enrollment
Given current uncertainty over safety and efficacy of immunosuppressive treatments, all patients who remain at high risk despite maximal supportive care should be offered participation in clinical trials 1.
Only 30.4% of nephrologists globally enroll patients with persistent proteinuria >1 g/d in clinical trials, with stark geographic disparities 2.
Global Inequities in Trial Access
Nephrologists in Europe (63.6%), North America (56.5%), and Australia (63.6%) are significantly more likely to enroll patients in trials compared to South America (31.3%) and Asia (17.2%) 2.
Only 8.1% of nephrologists in lower-middle income countries enroll patients in clinical trials, despite 40% being aware of such trials in their nations 2.
This disparity raises serious ethical concerns about equitable access to potentially beneficial novel therapies and the generalizability of trial results 2.
Treatment Threshold Controversies
Balancing Early Intervention vs. Overtreatment
The 2021 KDIGO guidelines lowered the proteinuria threshold for RAAS blockade from >1 g/d to >0.5 g/d, creating ethical questions about treating patients with mild disease 1.
Patients with mild albuminuria (30-300 mg/d) and normal blood pressure present an ethical dilemma, as the benefit of ACEI/ARB therapy is unclear given lack of data 1.
The guideline notes proteinuria >0.75 g/d correlates with high progression risk, yet suggests <1 g/d as the treatment target, creating ambiguity in the 0.75-1.0 g/d range 1.
Immunosuppression Decision Points
Immunosuppression should only be considered in patients with proteinuria >0.75-1 g/d despite ≥90 days of optimized supportive care 1.
The ethical challenge lies in identifying patients who warrant aggressive therapy versus those "past the point of no return" where risks outweigh benefits 1.
There is insufficient evidence to base treatment decisions solely on Oxford Classification MEST-C scores or crescent counts, requiring clinicians to navigate uncertainty 1.
Special Population Considerations
Adolescents and Young Adults
A critical ethical gap exists in treatment guidelines for adolescents and young adults transitioning from pediatric to adult care 3.
The absence of pediatric treatment recommendations in KDIGO guidelines due to lack of evidence creates ethical challenges for this vulnerable population 3.
Proposed approaches include RAAS blockade for proteinuria >0.5 g/day regardless of blood pressure, and corticosteroids for proteinuria >1 g/day, but these lack robust evidence 3.
Pregnancy Considerations
- Little guidance exists for managing IgAN in pregnancy, creating ethical challenges in balancing maternal kidney health against fetal safety 4.
Quality of Life and Patient-Centered Outcomes
Maximizing Comfort While Managing Disease
Treatment goals must balance benefits and risks while maximizing patient comfort and quality of life 1.
Patient-reported outcomes in clinical trials may draw more attention to quality of life issues that have been historically underemphasized 1.
The consideration of social and ethical aspects alongside clinical, histological, and laboratory factors is essential for tailored patient care 5.
Resource Allocation and Access
Medication Affordability
Despite encouraging data for SGLT2 inhibitors in nondiabetic kidney disease, utilization uptake has been slow due to barriers including cost and lack of universal insurance coverage 1.
This creates ethical disparities where evidence-based therapies remain inaccessible to patients based on socioeconomic status 1.
Geographic Variations in Practice
Significant heterogeneity exists globally in use of supportive therapies (fish oil 43.6%, SGLT2 inhibitors 48.6%) and initiation of immunosuppression 2.
These variations reflect not only evidence gaps but also resource availability and cultural factors that impact equitable care delivery 2.
Kidney Biopsy Ethics
Diagnostic Certainty vs. Procedural Risk
IgAN can only be diagnosed with kidney biopsy, but patients with preserved eGFR and lower proteinuria (<500 mg/g) require patient-centered discussion about biopsy utility 1.
Reasonable alternatives include watchful waiting, trial of antiproteinuric therapy, and serial monitoring, though this delays definitive diagnosis 1.
Treatment with aggressive immunosuppression usually warrants kidney biopsy for diagnostic and prognostic purposes, creating an ethical obligation to pursue tissue diagnosis before exposing patients to toxicity 1.